5.25
price up icon38.49%   1.4591
 
loading
Precedente Chiudi:
$3.7909
Aprire:
$5.87
Volume 24 ore:
36.44M
Relative Volume:
63.01
Capitalizzazione di mercato:
$11.72B
Reddito:
-
Utile/perdita netta:
$-60.61M
Rapporto P/E:
-5.8333
EPS:
-0.9
Flusso di cassa netto:
$-22.91M
1 W Prestazione:
+43.44%
1M Prestazione:
+63.04%
6M Prestazione:
+1,668%
1 anno Prestazione:
+540.40%
Intervallo 1D:
Value
$4.90
$7.7699
Intervallo di 1 settimana:
Value
$3.43
$7.7699
Portata 52W:
Value
$0.0815
$7.7699

Bioline Rx Ltd Adr Stock (BLRX) Company Profile

Name
Nome
Bioline Rx Ltd Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
28
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-26
Name
Ultimi documenti SEC
Name
BLRX's Discussions on Twitter

Confronta BLRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BLRX
Bioline Rx Ltd Adr
5.25 13.62M 0 -60.61M -22.91M -0.90
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2017-05-18 Aggiornamento Maxim Group Hold → Buy
2017-02-13 Iniziato Rodman & Renshaw Buy
2016-08-12 Downgrade Maxim Group Buy → Hold
2015-08-17 Reiterato Maxim Group Buy
2015-07-27 Reiterato ROTH Capital Buy
2015-06-22 Iniziato JMP Securities Mkt Outperform
Mostra tutto

Bioline Rx Ltd Adr Borsa (BLRX) Ultime notizie

pulisher
12:26 PM

BioLineRx ADR: Positive Earnings Call Highlights and Challenges - MSN

12:26 PM
pulisher
May 30, 2025

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating By Stocktwits - Investing.com India

May 30, 2025
pulisher
May 30, 2025

BioLineRx announces new data from Phase 2 combination trial of motixafortide - TipRanks

May 30, 2025
pulisher
May 30, 2025

Jones Trading raises BioLineRx stock rating, targets $12 By Investing.com - Investing.com India

May 30, 2025
pulisher
May 30, 2025

Jones Trading raises BioLineRx stock rating, targets $12 - Investing.com

May 30, 2025
pulisher
May 30, 2025

BioLineRx upgraded to Buy from Hold at JonesResearch - TipRanks

May 30, 2025
pulisher
May 30, 2025

BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial - TipRanks

May 30, 2025
pulisher
May 30, 2025

BioLineRx reports promising pancreatic cancer trial data By Investing.com - Investing.com India

May 30, 2025
pulisher
May 30, 2025

BioLineRx reports promising pancreatic cancer trial data - Investing.com

May 30, 2025
pulisher
May 28, 2025

Jones Trading maintains Hold on BioLineRx stock amid royalty prospects By Investing.com - Investing.com India

May 28, 2025
pulisher
May 28, 2025

H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock - Investing.com

May 28, 2025
pulisher
May 28, 2025

BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks

May 28, 2025
pulisher
May 27, 2025

BioLineRx Ltd. Reports Q1 2025 Financial Results - TipRanks

May 27, 2025
pulisher
May 27, 2025

BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident By Stocktwits - Investing.com India

May 27, 2025
pulisher
May 27, 2025

BioLineRx Reports Q1 2025 Financial Results and Strategic Updates - TipRanks

May 27, 2025
pulisher
May 27, 2025

Options Volatility and Implied Earnings Moves Today, May 27, 2025 - TipRanks

May 27, 2025
pulisher
May 23, 2025

BioLineRx Ltd. Schedules Annual Shareholder Meeting for June 2025 - TipRanks

May 23, 2025
pulisher
May 09, 2025

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail

May 09, 2025
pulisher
Apr 01, 2025

BioLineRx stock rating cut to Hold at Jones Trading - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright raises BioLineRx stock target to $26 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025 - The Globe and Mail

Mar 31, 2025
pulisher
Mar 31, 2025

BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Options Volatility and Implied Earnings Moves Today, March 31, 2025 - TipRanks

Mar 31, 2025
pulisher
Mar 07, 2025

Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Feb 27, 2025

Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 19, 2025

BLRX: Aphexda Transition Progressing - Research Tree

Feb 19, 2025
pulisher
Jan 31, 2025

BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com India

Jan 31, 2025
pulisher
Jan 21, 2025

BioLineRx announces strategic shift with licensing deals - Investing.com

Jan 21, 2025
pulisher
Jan 21, 2025

BioLineRx Outlines Strategic Vision and Financial Outlook After Key Licensing Deals - TipRanks

Jan 21, 2025
pulisher
Jan 17, 2025

BioLineRx Adjusts ADS Ratio to Maintain Nasdaq Listing - TipRanks

Jan 17, 2025
pulisher
Jan 17, 2025

BioLineRx Announces 1:40 ADS Ratio Change, Confirms $29.5M Cash Runway Through 2026 - Stock Titan

Jan 17, 2025
pulisher
Jan 13, 2025

BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

BioLineRx stock touches 52-week low at $0.14 amid downturn By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 07, 2025

BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks

Jan 07, 2025
pulisher
Jan 06, 2025

BioLineRx stock plunges to 52-week low of $0.19 amid market challenges - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

BioLineRx Announces $10 Million Direct Offering to Fuel Growth - TipRanks

Jan 06, 2025
pulisher
Jan 06, 2025

BioLineRx Raises $10M in Direct Offering at $0.20 Per ADS with Matching Warrants - Stock Titan

Jan 06, 2025
pulisher
Dec 16, 2024

BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com

Dec 16, 2024
pulisher
Dec 06, 2024

BioLineRx stock plunges to 52-week low, hits $0.25 - Investing.com India

Dec 06, 2024
pulisher
Nov 26, 2024

BioLineRx stock target cut, retains buy on Q3 financial results - Investing.com

Nov 26, 2024
pulisher
Nov 25, 2024

BioLineRx Reports Strategic Moves in Q3 2024 - TipRanks

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx earnings beat by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa

Nov 25, 2024
pulisher
Nov 25, 2024

Earnings call: BioLineRx announces Q3 results and strategic shifts - Investing.com

Nov 25, 2024
pulisher
Nov 25, 2024

Earnings call: BioLineRx announces Q3 results and strategic shifts By Investing.com - Investing.com South Africa

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx Secures Key Deals to Boost Shareholder Value - TipRanks

Nov 25, 2024
pulisher
Nov 22, 2024

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance

Nov 22, 2024
pulisher
Nov 21, 2024

BiolineRx Ltd. Announces New Direct Offering of Shares - TipRanks

Nov 21, 2024

Bioline Rx Ltd Adr Azioni (BLRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):